FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
Decision brief
Answer first · skim in under a minute
The FDA approved pembrolizumab (Keytruda) for adjuvant treatment of stage IB, II, and IIIA non-small cell lung cancer after resection and platinum chemotherapy. For Merck and investors, the key readout is how this label expansion may shape lung cancer franchise momentum and future catalyst tracking.
On January 26, 2023, the FDA approved pembrolizumab (Keytruda) for adjuvant use after surgery and platinum chemo in stage IB–IIIA NSCLC. For teams watching Merck Keytruda price and lifecycle value, the KEYNOTE-091 disease-free survival gain is the clinical catalyst behind the new label.
Contents10 sections
Key Takeaways
- FDA approved adjuvant Keytruda on January 26, 2023, for resected stage IB (T2a ≥4 cm), II, or IIIA NSCLC after platinum-based chemotherapy.
- KEYNOTE-091 (NCT02504372) randomized 1,177 patients; 86% received adjuvant platinum chemo.
- Among chemo-treated patients, median DFS was 58.7 months versus 34.9 months for placebo (HR 0.73).
- Merck Keytruda price is not set by the approval letter; dosing is 200 mg q3w or 400 mg q6w for up to 1 year.
What did the FDA approve for adjuvant Keytruda?
The FDA cleared pembrolizumab as a single agent after complete resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer.
The agency’s notice is the primary record of the labeled population. See the FDA adjuvant pembrolizumab approval.
How strong were KEYNOTE-091 disease-free survival results?
KEYNOTE-091 was a multicenter, randomized, triple-blind, placebo-controlled Phase 3 trial. Patients had not received neoadjuvant radiotherapy or chemotherapy. They were assigned 1:1 to pembrolizumab 200 mg or placebo every 3 weeks for up to 1 year.
Of 1,177 patients randomized, 1,010 (86%) received adjuvant platinum-based chemotherapy after resection. For that chemo-treated group, median DFS was 58.7 months with pembrolizumab versus 34.9 months with placebo (HR 0.73; 95% CI 0.60–0.89). In 167 patients who did not receive adjuvant chemo, the exploratory DFS HR was 1.25 (95% CI 0.76–2.05).
Trial registration: NCT02504372 on ClinicalTrials.gov. Peer-reviewed interim results are on PubMed (PMID 36108662).
Dosing, safety, and labeled use limits
Labeled adjuvant dosing is 200 mg every 3 weeks or 400 mg every 6 weeks, for up to 1 year, as monotherapy after surgery and platinum chemo.
- Hypothyroidism 22%, hyperthyroidism 11%, and pneumonitis 7% stood out versus other NSCLC single-agent Keytruda experience.
- Two fatal myocarditis events occurred in KEYNOTE-091.
- This indication does not, by itself, cover neoadjuvant-only or unresected metastatic use.
What Merck Keytruda price watchers should separate from the label
The January 2023 FDA action expands the treated population in early-stage NSCLC. It does not publish a U.S. list price or net price. Merck Keytruda price tracking still depends on contracting, 340B, and payer policies outside the approval text.
Merck’s own announcement framed the same DFS numbers (27% lower risk of recurrence or death versus placebo in the chemo-treated group). Investors should treat clinical DFS and commercial price as separate workstreams.
How this fits Merck’s early-stage lung cancer franchise
Adjuvant Keytruda adds a post-surgery, post-chemo option in resected IB–IIIA disease. Teams comparing franchise catalysts should read the FDA notice alongside the KEYNOTE-091 protocol, not competitor news alone.
Related disease context: lung cancer coverage on NovaPharmaNews.
What remains unproven from the approval alone
Overall survival maturity, real-world adherence to 1-year adjuvant dosing, and any net-price impact from the broader early-stage pool are not settled by the approval notice. The exploratory no-chemo subgroup did not show a DFS benefit (HR 1.25), so claims for that slice should not be overstated.
Related NovaPharma coverage
- FDA approves Merck’s Keytruda for adjuvant NSCLC treatment
- FDA approves Keytruda adjuvant NSCLC, a Merck catalyst
- Pembrolizumab drug profile
Frequently Asked Questions
When did the FDA approve Keytruda for adjuvant NSCLC?
On January 26, 2023, the FDA approved pembrolizumab (Keytruda, Merck) for adjuvant treatment after resection and platinum-based chemotherapy in stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
What KEYNOTE-091 results supported the approval?
In patients who received adjuvant platinum chemotherapy, median disease-free survival was 58.7 months with pembrolizumab versus 34.9 months with placebo (hazard ratio 0.73; 95% CI 0.60–0.89). The trial enrolled 1,177 patients (NCT02504372).
Does the adjuvant label set Merck Keytruda price?
No. The FDA label defines the indicated population and dosing (200 mg every 3 weeks or 400 mg every 6 weeks for up to 1 year). List price, contracting, and reimbursement are separate commercial decisions not stated in the January 2023 approval notice.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for pembrolizumab.
Unlock full calendar →Merck & Co. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…